Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q3 EPS of ($0.36), $0.01 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $5.18 million versus the consensus estimate of $16.95 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.